Specialty Medicine Compounding Pharmacy Recalls Ceftazidime Ophthalmic Solution
Specialty Medicine Compounding Pharmacy is recalling Ceftazidime ophthalmic solution because sterility cannot be assured due to shared compounding practices with a non-sterile product.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, and the rubric specifies that FDA Class II recalls with potential for serious injury (such as sterility failure in ophthalmic products) are rated as Severe.
Plain-English summary
Specialty Medicine Compounding Pharmacy is recalling all unexpired lots of Ceftazidime, 22.5 mg/ml (ophthalmic), Rx only. The affected product was manufactured and distributed between July 1, 2013, and October 19, 2013, and includes Lot # 08222013@3. The product quantity is 44.44 mL.
The recall is being conducted because the product was compounded in the same environment and under the same practices as another product found to be non-sterile. Consequently, the sterility of the recalled Ceftazidime cannot be assured. This lack of assurance of sterility applies to all unexpired sterile compounded human and veterinary products from the facility.
The affected product was distributed to hospitals, clinics, physicians, and patients in the Michigan area only. Consumers and healthcare providers should stop using the recalled product and contact their healthcare provider or the recalling firm for further instructions.
The recalled product
- Product
- Ceftazidime, 22.5 mg/ml (ophthalmic), Rx only, Specialty Medicine Compounding Pharmacy, 350 S Lafayette, South Lyon, MI 48178
- Manufacturer
- Specialty Medicine Compounding Pharmacy
- Category
- Drug — Ophthalmic
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- All unexpired lots
- manufactured and distributed between 07/01/2013 and 10/19/2013
- including Lot #: 08222013@3
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 51 recalled by Specialty Medicine Compounding Pharmacy under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 51 products in this recall →Related recalls
Same manufacturer · Specialty Medicine Compounding Pharmacy
See all →- Severe
- SevereSpecialty Medicine Compounding Pharmacy Recalls Combo Eye Gel Due to Sterility Concerns
FDA (Drugs) · 2014-01-22
- SevereHyaluronidase Recalled Due to Lack of Assurance of Sterility
FDA (Drugs) · 2014-01-22
- SeverePhenol Injectable Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2014-01-22
- SevereCyanocobalamin Injectable Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2014-01-22
Same hazard · sterility failure
See all →- SevereAvKare Carboxymethylcellulose Sodium Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereAvKare Carboxymethylcellulose Sodium Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereROHTO DIGI-EYE Eye Drops Recalled Over Sterility Assurance Gap
FDA (Drugs) · 2026-07-29
- HighROHTO DRY-AID Eye Drops Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- SevereOne-Piece Introducer Tray kits recalled for sterility failure
FDA (Devices) · 2026-07-22
Similar recalls
- HighCeftazidime Intravitreal Solution Recalled for Sterility Assurance Failure
FDA (Drugs) · 2022-11-09
- SevereWells Pharmacy Recalls Ceftazidime Ophthalmic Kits Due to Sterility Concerns
FDA (Drugs) · 2017-01-11
- HighCeftazidime Sterile Ophthalmic Solution Lacks Sterility Assurance
FDA (Drugs) · 2022-02-02
- SevereKey Pharmacy Recalls Sterile Ophthalmic Compounded Drug Due to Sterility Concerns
FDA (Drugs) · 2017-05-24
- SevereEdge Pharma Recalls Ceftazidime Sterile Ophthalmic Solution Due to Sterility Concerns
FDA (Drugs) · 2021-01-27
- SevereCreative Compounds Recalls Ceftazidime Syringes Due to Sterility Concerns
FDA (Drugs) · 2014-11-12